Term of patent in the United States

Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates

Retrieved on: 
Thursday, May 13, 2021
Patent law, Communication, Forward-looking statement, United States patent law, Articles, Term of patent in the United States, Patent, Term of patent

This patent expires in 2038, not including any patent term extensions.

Key Points: 
  • This patent expires in 2038, not including any patent term extensions.
  • Actual results may differ materially from those expressed or implied by such forward-looking statements.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.
  • Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Palatin Announces U.S. Patent Term Extension for Vyleesi® (bremelanotide injection)

Retrieved on: 
Tuesday, May 4, 2021
Intellectual property law, Patent law, Term of patent in the United States, United States patent law, Intellectual property organizations, Term of patent, International Searching and Preliminary Examining Authorities, Patent offices, Bremelanotide, Drug Price Competition and Patent Term Restoration Act, United States Patent and Trademark Office, Patent

For more information on Vyleesi, go to www.vyleesi.com .\nThe patent term extension is pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly called the Hatch-Waxman Amendments, which permits an extension of the term of one patent for a maximum period of five years as compensation for patent term lost during drug development and the FDA regulatory review process.

Key Points: 
  • For more information on Vyleesi, go to www.vyleesi.com .\nThe patent term extension is pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly called the Hatch-Waxman Amendments, which permits an extension of the term of one patent for a maximum period of five years as compensation for patent term lost during drug development and the FDA regulatory review process.
  • An interim extension for a period of one year from the original expiration date of both patents of June 25, 2020, was granted by the USPTO in May 2020.
  • In the Notices of Final Determination issued by the USPTO, the maximum allowable five-year extension was granted.\nPalatin has filed an Election to extend the patent term of U.S. patent 6,794,489.
  • Palatin is not responsible for updating for events that occur after the date of this press release.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/palatin-announces-us-patent-term...\n'

U.S. Patents for Nicox’s Latanoprostene Bunod, Commercialized as VYZULTA®, Eligible for Patent Term Extension

Retrieved on: 
Thursday, April 22, 2021
Intellectual property law, Patent law, United States patent law, NicOx, Term of patent in the United States, Term of patent, United States Patent and Trademark Office, Patent

Patents for Nicox\xe2\x80\x99s Latanoprostene Bunod, Commercialized as VYZULTA\xc2\xae, Eligible for Patent Term Extension\nNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the United States Patent and Trademark Office (USPTO) has determined that three U.S. composition of matter patents covering latanoprostene bunod, commercialized as VYZULTA\xc2\xae (latanoprostene bunod ophthalmic solution), 0.024%, are eligible for patent term extension, potentially through to 2030.\nThe initial patent term of the latanoprostene bunod patents concerned is 2025.

Key Points: 
  • Patents for Nicox\xe2\x80\x99s Latanoprostene Bunod, Commercialized as VYZULTA\xc2\xae, Eligible for Patent Term Extension\nNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the United States Patent and Trademark Office (USPTO) has determined that three U.S. composition of matter patents covering latanoprostene bunod, commercialized as VYZULTA\xc2\xae (latanoprostene bunod ophthalmic solution), 0.024%, are eligible for patent term extension, potentially through to 2030.\nThe initial patent term of the latanoprostene bunod patents concerned is 2025.
  • Nicox believes that each of these patents could be extended by almost the maximum 5 years allowable.
  • The duration of this patent extension is subject to calculation by the U.S. Food and Drug Administration (FDA) with the final decision of the USPTO regarding the term of the extension expected in two to three years.
  • Nicox disavows any obligation to correct or to update the information contained in analyst reports.\n'

Tauriga Sciences, Inc. Converts its U.S. Provisional Patent Application (Filed on March 17, 2020) to a U.S. Non-Provisional Patent Application

Retrieved on: 
Monday, March 22, 2021
United States patent law, Monopoly, Patent law, Provisional application, Patent application, Chewing gum, Patent, Term of patent in the United States, Business law, Outline of patents

Provisional Patent Application (filed on March 17, 2020) to a U.S. Non-Provisional Patent Application.

Key Points: 
  • Provisional Patent Application (filed on March 17, 2020) to a U.S. Non-Provisional Patent Application.
  • This Non-Provisional Patent Application relates to the Companys proposed Pharmaceutical Cannabinoid Chewing Gum Delivery System being developed to treat: Nausea Derived from Active Chemotherapy Treatment.
  • Also on March 17, 2021, to enhance its existing intellectual property (IP) portfolio, the Company filed an additional U.S.
  • On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum.

Clarification of Previously Announced Press Release: SoLVBL Solutions Inc. Announces Update on the Second Provisional Patent Application

Retrieved on: 
Tuesday, March 9, 2021
Intellectual property law, United States patent law, Intangible assets, International Searching and Preliminary Examining Authorities, Patent offices, Provisional application, Patent, United States Patent and Trademark Office, Trademark, Term of patent in the United States, Outline of patents

Provisional Patent Application" (the "Original Press Release").

Key Points: 
  • Provisional Patent Application" (the "Original Press Release").
  • Due to recent queries regarding the Original Press Release, the following press release provides additional information and clarification on certain statements regarding filing of the Second U.S.
  • Provisional Patent Application with the United States Patent and Trademark Office (the "Second U.S.
  • In the Original Press Release, the Company set out the parameters of the Second U.S.

Palatin Technologies Announces Filing of International Patent Application Claiming PL9643

Retrieved on: 
Wednesday, February 10, 2021
Countries, Government, Foreign relations, Patent law, Term of patent in the United States, Term of patent, Patent application, Patent, Priority right, Outline of patents, European Patent Convention

Palatin recently reported positive results in its Phase 2 study of PL9643 for the treatment of Dry Eye Disease (DED).

Key Points: 
  • Palatin recently reported positive results in its Phase 2 study of PL9643 for the treatment of Dry Eye Disease (DED).
  • A Phase 2/3 clinical trial with PL9643 for the treatment of DED is currently planned for mid-2021.
  • The PCT application for PL9643 establishes the base for the presumptive patent term, and if a patent is granted which claims priority to this application, could provide patent protection for PL9643, and any product in which PL9643 is the active pharmaceutical ingredient, out to 2041, excluding any additional term for patent adjustment or patent term extension.
  • We anticipate filing patent applications in the United States, Europe and a number of additional regions and countries throughout the world.

Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027

Retrieved on: 
Friday, February 5, 2021
Biotechnology, Pharmaceutical, Health, Chemical compounds, Intellectual property law, Organic compounds, Intangible assets, Protein kinase inhibitors, Cyclopentanes, Piperazines, Breakthrough therapy, Palbociclib, United States Patent and Trademark Office, Term of patent in the United States, Term of patent, IBRANCE® (palbociclib) 125 mg tablets and capsules, Pfizer Oncology, Pfizer: Breakthroughs That Change Patients’ Lives

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Patent and Trademark Office (USPTO) recently issued a U.S. Patent Term Extension (PTE) certificate for IBRANCE (palbociclib).

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced that the U.S. Patent and Trademark Office (USPTO) recently issued a U.S. Patent Term Extension (PTE) certificate for IBRANCE (palbociclib).
  • The PTE certificate was granted under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984.
  • In PALOMA-2, Grade 3 (56%) or 4 (10%) decreased neutrophil counts were reported in patients receiving IBRANCE plus letrozole.
  • In PALOMA-3, Grade 3 (55%) or Grade 4 (11%) decreased neutrophil counts were reported in patients receiving IBRANCE plus fulvestrant.

Canntab Granted 2nd Patent For Immediate Release Cannabidiol Formulation Tablets

Retrieved on: 
Monday, February 1, 2021
Intellectual property law, Patent law, Patent application, United States Patent and Trademark Office, Patent, United States patent law, Term of patent in the United States, Outline of patents

CA 3050150 to Canntab, related toits proprietary cannabidiol formulations with a priority date of January 23, 2017.

Key Points: 
  • CA 3050150 to Canntab, related toits proprietary cannabidiol formulations with a priority date of January 23, 2017.
  • The Company now has patent protection in Canada and the USA providing an international scope to the Company's expanding portfolio of issued patents."
  • Canntab has filed more than a dozen patent applications in the United States and Canada for which two have now been granted or allowed.
  • On September 21, 2020 Canntab had announced that pursuant to a filing made inMarch 2017, the U.S. Patent and Trademark Office (USPTO) had issued U.S. Patent No.

Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office

Retrieved on: 
Thursday, August 27, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Intellectual property law, Patent law, Intellectual property organizations, Term of patent in the United States, United States Patent and Trademark Office, United States patent law, Term of patent, Patent, Title 35 of the United States Code, CRTX

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimers and other degenerative diseases, announced today that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No.

Key Points: 
  • Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimers and other degenerative diseases, announced today that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No.
  • Cortexyme's 826 patent provides additional composition of matter protection for atuzaginstat and gingipain inhibitors, with additional claims pending in related applications.
  • The patent is expected to provide patent protection for atuzaginstat through September 2037, not including a possible patent term extension of up to five years as provided under the Drug Price Competition and Patent Restoration Act (35 U.S.C.
  • The USPTO's issuance of this patent strengthens our intellectual property protection for gingipain inhibitors and atuzaginstat.

Emerald Health Pharmaceuticals Expands Global Technology Protection with the Granting of Six New International Patents

Retrieved on: 
Monday, March 16, 2020
Health, Articles, Pharmaceuticals policy, Food and Drug Administration, United States Public Health Service, Pharmaceutical industry, Term of patent in the United States

The granting of these patents further expands the protection of our platform technology, said Jim DeMesa, MD, President & CEO of Emerald Health Pharmaceuticals.

Key Points: 
  • The granting of these patents further expands the protection of our platform technology, said Jim DeMesa, MD, President & CEO of Emerald Health Pharmaceuticals.
  • The patents and patent applications currently provide protection to 2040 and could be eligible for patent term extension.
  • About Emerald Health Pharmaceuticals Inc.
    Emerald Health Pharmaceuticals is developing novel product candidates derived from cannabinoids for the treatment of CNS, autoimmune, fibrotic and other diseases.
  • Emerald Health Pharmaceuticals' investigational drug products have not been approved or cleared by the FDA.